Brukinsa

Brukinsa is a medicine for treating adults with the following types of blood cancers that affect a type of white blood cell called B lymphocytes or B cells: - Waldenström’s macroglobulinaemia (also known as lymphoplasmacytic lymphoma). Brukinsa is used on its own in patients who have not been treated before and who cannot receive chemo-immunotherapy (a type of cancer treatment), or in patients who have received at least one prior therapy; - Marginal zone lymphoma (MZL). Brukinsa is used on its own when the disease has come back after at least one prior therapy targeting a protein on B lymphocytes called CD20; - Chronic lymphocytic leukaemia (CLL). Brukinsa is used on its own in patients for the treatment of CLL. - Follicular lymphoma (FL). Brukinsa is used in combination with another cancer medicine, obinutuzumab, in adult patients whose disease has come back or has not responded to at least two prior therapies. Brukinsa contains the active substance zanubrutinib.